Drivetime Specialty is a free educational audio program covering a range of topics relevant to various medical specialists & physicians. Listen to our experienced medical broadcasters, moderating engaging discussions with leading experts.
Current disciplines include:
A podcast of the specialty series is available to download, providing a time efficient form of communication that’s convenient and easy to consume. Click here for podcast download instructions You can also listen online – search by your area of interest to filter interviews relevant to you.
Interviews are provided exclusively for Australian healthcare professionals. Subscribe for free today to access all programs.
Psychiatry: Respiratory: The onset of schizophrenia commonly occurs during adolescence and young adulthood. Tolerability and safety concerns are of particular importance in treatment selection because adolescents may be more vulnerable to adverse effects associated with medications. In this interview we talk with Prof. Thompson from EPPIC, EPPIC works with young people with psychotic disorders and aims to facilitate the early identification and treatment of psychosis and therefore reduce the disruption to the young person’s functioning and psychosocial development.
Psychiatry: Sexual difficulties are common. They’re even more common in people who are depressed. And they’re even more common again in depressed people who are taking antidepressant therapies. It’s important to include sexual functioning as a routine part of practice, however, talking about sex and sexual dysfunction is still often an uncomfortable topic of discussion for both patients and their psychiatrist. In this interview we discuss the when, where and how?
Respiratory: ‘Real world evidence’ is a bit of a buzz word in research circles at the moment. Increasingly this type of evidence is being used to inform both regulatory and payor decision-making. But what does it mean clinically? And should we be paying attention? In this interview we discuss real world evidence, with a particular focus on severe asthma biologics.
The Australian Mepolizumab Registry is an investigator-initiated and managed study funded through the GlaxoSmithKline Investigator-Sponsored Studies program
Respiratory: Up until now, the treatment for severe asthma with biologic medications has been predominantly administered by healthcare practitioners. In this interview, we’ll explore the paradigm shift towards patients self-administering biologic treatments. How do we choose patients who are suitable for self-administration? How might empowering patients to self-administer treatment reduce current barriers faced by patients and improve convenience?
Epilepsy: What are the most significant understandings in genetics that have happened over the last few years, and what have been the big breakthroughs? In this interview we present a remarkable view of this incredibly wide ranging field, where there have been so many dramatic developments. We provide a valuable background and some practical advice about what we can say to patients, and how to approach screening issues.
Epilepsy: Epilepsy is commonly diagnosed in adolescence, affecting approximately 1% of children aged 14 to 16 years. At a time of critical intellectual, physical, hormonal and social development, epilepsy can have a significant effect on the teenager’s lifestyle. Choosing the right anti-epileptic drug from the start can have significant benefits to teenagers, enabling them to gain the necessary independence and self-empowerment to mature through adolescence.
Dentist: This update for Dentists, explains the latest evidence and recommendations for minimising the risk for ONJ and maintaining fracture protection in patients being treated for osteoporosis.
Psychiatry: In this interview we discuss major depressive disorder (MDD) in all its complexity and the challenge it presents to us. MDD not only impacts a patient’s mood, but also their social lives, their professional lives and of course their family and other relationships. We discuss these issues in the setting of treatment choices and the importance of identifying and treating the constellation of MDD symptoms in practice.
Psychiatry: We will often identify psychotic symptoms and be responsible for considering antipsychotic therapy in patients who are treatment naïve. In this interview we look at the considerations that are important when we are contemplating treatment choice.
Psychiatry: Conventionally during the acute phase of psychosis, we’ve tended to focus on short-term treatment of intense positive symptoms, hostility and agitation, and may not consider long-term treatment goals such as the improvement of negative symptoms and cognitive deficits the way we might like. In this interview, we’re talking about the importance of considering long-term treatment goals of schizophrenia when treating patients with psychosis in the acute phase.
Tap the share icon and select 'Add to Home Screen' to add the site to your home screen for quick access!